Literature DB >> 24551671

A comparative study to evaluate the efficacy and safety of acyclovir and famciclovir in the management of herpes zoster.

M G Gopal1, Sharath Kumar B C2, Ramesh M3, Nandini A S4, Namrata C Manjunath5.   

Abstract

BACKGROUND: Over the years, acyclovir has been the oral antiviral agent approved for the treatment of patients with acute herpes zoster,Its effectiveness in lessening the acute signs and symptoms of herpes zoster has been established but the effects on post herpetic neuralgia are less clear cut. Famciclovir is a new member of guanine nucleoside family of drugs. It is a well absorbed oral form of penciclovir with longer half life. This was a open comparative randomized study carried out to compare the safety and efficacy of famciclovir administered at 250mg thrice daily with acyclovir 800mg five times daily for the treatment of acute uncomplicated herpes zoster in immunocompetent individuals aged above 40 years. AIM: To assess the clinical profile of Herpes zoster, compare the efficacy and safety of acyclovir and famciclovir in the treatment of herpes zoster and to describe the effectiveness of acyclovir and famciclovir preventing post herpetic neuralgia.
METHODS: A total of 100 newly zoster were randomized in 1:1 ratio into acyclovir and famciclovir groups after inclusion criteria were satisfied.Treatment was initiated within 72 hrs of onset of symptoms and was continued for 7 days and evaluated at the end of each week up to six weeks period for full crusting of the lesions, complete healing of the lesion and loss of acute pain.
RESULTS: It was observed that famciclovir was as effective as acyclovir with no significant difference in time taken for full crusting, complete healing of lesions or loss of acute pain. Famciclovir was well tolerated with a better safety profile comparable to that of acyclovir. Constipation, headache, nausea and vomiting were the most commonly reported adverse effects, but constipation was considered to have a possible relationship to treatment.
CONCLUSION: In conclusion, oral famciclovir administered three times daily for 7 days during acute zoster infection is as effective as acyclovir, administered 800mg five times daily.In addition it offers significant benefit by providing a well tolerated, cost effective, convenient dosage regime and accelerated rate of lesion resolution and a reduced duration of PHN.

Entities:  

Keywords:  Acyclovir; Famciclovir; Primary herpetic neuralgia

Year:  2013        PMID: 24551671      PMCID: PMC3919380          DOI: 10.7860/JCDR/2013/7884.3670

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  7 in total

1.  Therapy of herpes zoster with oral acyclovir.

Authors:  J C Huff; B Bean; H H Balfour; O L Laskin; J D Connor; L Corey; Y J Bryson; P McGuirt
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

Review 2.  Acute herpetic and postherpetic neuralgia: clinical review and current management.

Authors:  R K Portenoy; C Duma; K M Foley
Journal:  Ann Neurol       Date:  1986-12       Impact factor: 10.422

Review 3.  Herpes zoster and postherpetic neuralgia.

Authors:  John D Loeser
Journal:  Pain       Date:  1986-05       Impact factor: 6.961

Review 4.  Human infection with herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment.

Authors:  G L Strommen; F Pucino; R R Tight; C L Beck
Journal:  Pharmacotherapy       Date:  1988       Impact factor: 4.705

5.  Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial.

Authors:  Stephen D Shafran; Stephen K Tyring; Richard Ashton; Jacque Decroix; Chistine Forszpaniak; Alan Wade; Christian Paulet; Daniel Candaele
Journal:  J Clin Virol       Date:  2004-04       Impact factor: 3.168

6.  Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster.

Authors:  Meng-Chuan Shen; Hsi-Hsun Lin; Susan Shin-Jung Lee; Yao-Shen Chen; Ping-Chen Chiang; Yung-Ching Liu
Journal:  J Microbiol Immunol Infect       Date:  2004-04       Impact factor: 4.399

7.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

  7 in total
  5 in total

Review 1.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 2.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

Review 3.  Comparing Prodrugs with Acyclovir for Treating Postherpetic Neuralgia among Herpes Zoster Patients: A Systematic Review and Meta-Analysis.

Authors:  Chung-Hsin Yeh; Ko-Shih Chang; Sheng-Shiung Huang; Shiow-Luan Tsay; Jung-Mei Tsai; Ya-Jung Wang
Journal:  Healthcare (Basel)       Date:  2022-06-24

Review 4.  New strategies against drug resistance to herpes simplex virus.

Authors:  Yu-Chen Jiang; Hui Feng; Yu-Chun Lin; Xiu-Rong Guo
Journal:  Int J Oral Sci       Date:  2016-03-30       Impact factor: 6.344

5.  Herbal Gel Formulation Developed for Anti-Human Immunodeficiency Virus (HIV)-1 Activity Also Inhibits In Vitro HSV-2 Infection.

Authors:  Nripendra Nath Mishra; Ajay Kesharwani; Aakanksha Agarwal; Suja Kizhiyedath Polachira; Reshmi Nair; Satish Kumar Gupta
Journal:  Viruses       Date:  2018-10-24       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.